|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||241.71 - 249.62|
|52-week range||241.71 - 249.62|
|Beta (5Y monthly)||0.75|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
McKesson (MCK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Investors are optimistic about Omnicell (OMCL) on strength in medication management and adherence automation solutions.
McKesson (MCK) is well positioned to outperform the market, as it exhibits above-average growth in financials.